Induction of Apoptosis by Cross-Linking Antibodies Bound to Human B-Lymphoma Cells: Expression of Annexin V Binding Sites on the Antibody Cap
Authors:
- 1 April 2009
- journal article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 24 (2) , 185-193
Abstract
There are many reports that cross-linking antibodies (Abs) bound to the surface of B-lymphoma cells can induce apoptosis and/or cell death, especially with anti-CD20 Abs. This study was intended to extend our understanding of these effects. To determine if CD20 is a unique target in this respect, or whether Abs to other antigens would have similar effects, six Abs were tested, with and without cross-linking with a secondary Ab, on three target cell lines. We utilized assays that distinguish between apoptotic, dead, and viable cells. Two assays were used: Annexin V plus propidium iodide, and JC-1 plus SYTOX green (Molecular Probes, Eugene, OR). Most of the Abs tested induced a low level of apoptosis and cell death in Ramos cells, but not in the other two cell lines (Raji and RL). In general, the level of toxicity was correlated with the level of antigen expression, with Abs to high-density antigens having the strongest effects. However, since the majority of Ramos cells continued to multiply, it is questionable whether toxicity at this level can provide a significant clinical benefit. Unexpectedly, there was also a population of cells that stained weakly with Annexin V. These cells were distinct from classical apoptotic cells, and appeared to belong to the viable cell population. In these cells, Annexin V stained the region of the Ab cap, in contrast to the ringed staining of classical apoptotic cells. 1) Low-level induction of apoptosis was not unique for anti-CD20 Abs, but occurred similarly with other Abs, and 2) results of Annexin V staining experiments may need to be reevaluated. Further studies are required to explain why Annexin V binding sites are exposed in the region of an Ab cap.Keywords
This publication has 42 references indexed in Scilit:
- Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of actionBlood, 2008
- The mechanism of killing of B-lymphoma cells by111In-conjugated antibodiesInternational Journal of Radiation Biology, 2008
- Apoptosis assays with lymphoma cell lines: problems and pitfallsBritish Journal of Cancer, 2007
- Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targetingProceedings of the National Academy of Sciences, 2006
- Characterization of antibody-containing vesicles shed from B-lymphoma cell lines: exposure of annexin V binding sitesLeukemia & Lymphoma, 2006
- A Novel Anti-human DR5 Monoclonal Antibody with Tumoricidal Activity Induces Caspase-dependent and Caspase-independent Cell DeathJournal of Biological Chemistry, 2005
- Cholesterol depletion inhibits src family kinase‐dependent calcium mobilization and apoptosis induced by rituximab crosslinkingImmunology, 2005
- Enhanced Apoptosis and Tumor Regression Induced by a Direct Agonist Antibody to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor 2Clinical Cancer Research, 2005
- Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s LymphomaClinical Cancer Research, 2004
- Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistanceOncogene, 2003